Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...

Prophylactic tocilizumab has the potential to decrease cytokine release syndrome and neurotoxicity for bispecific antibodies, explained Robert Rifkin, MD, FACP, a medical oncologist and ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Table 3. Incidence of Grade ≥3 TEAEs Occurring in ≥10% of Patients Across Cohorts, Regardless of Attribution One patient with grade 3 CRS received tocilizumab in cohort 1 and three patients with grade ...

This is even without mandating preventative treatment like tocilizumab, and that paints as good a picture as we can see about the safety for now. Risk — CAR T-cell therapy is an aggressive ...

Comparator drugs in the analysis included Janus kinase (JAK) inhibitors such as tofacitinib (Xeljanz) and biologics with non-TNF targets, including abatacept (Orencia), tocilizumab (Actemra), and ...